Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - GoodwillEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Long-Term Debt Issuances (2016 - 2021)

Historic Long-Term Debt Issuances for Harvard Bioscience (HBIO) over the last 12 years, with Q4 2021 value amounting to $1.8 million.

  • Harvard Bioscience's Long-Term Debt Issuances fell 9661.51% to $1.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $59.4 million, marking a year-over-year increase of 393.36%. This contributed to the annual value of $4.2 million for FY2021, which is 9306.86% down from last year.
  • Latest data reveals that Harvard Bioscience reported Long-Term Debt Issuances of $1.8 million as of Q4 2021, which was down 9661.51% from $2.5 million recorded in Q3 2021.
  • Harvard Bioscience's 5-year Long-Term Debt Issuances high stood at $67.0 million for Q1 2018, and its period low was -$100000.0 during Q4 2018.
  • Its 5-year average for Long-Term Debt Issuances is $9.8 million, with a median of $1.9 million in 2019.
  • Data for Harvard Bioscience's Long-Term Debt Issuances shows a peak YoY increase of 660000.0% (in 2018) and a maximum YoY decrease of 12000.0% (in 2018) over the last 5 years.
  • Harvard Bioscience's Long-Term Debt Issuances (Quarter) stood at $500000.0 in 2017, then tumbled by 120.0% to -$100000.0 in 2018, then skyrocketed by 2100.0% to $2.0 million in 2019, then surged by 2485.0% to $51.7 million in 2020, then tumbled by 96.62% to $1.8 million in 2021.
  • Its last three reported values are $1.8 million in Q4 2021, $2.5 million for Q3 2021, and $51.7 million during Q4 2020.